A newreport - developed by R-Health Consult and commissioned for EFPIA - provides an analysis of the economic and health benefits of investment in five key non-communicable diseases (NCDs).
The research looks at stroke, ischaemic heart disease, type 2 diabetes, chronic obstructive pulmonary disease (COPD), and breast cancer across the 27 European Union Member States and makes recommendations on how to reduce mortality, improve quality of life for patients while improving return on investments (ROI) for the European economy.
It shows that substantial ROI can be made from targeted health interventions; it uses specific insights from case studies in three countries - Portugal, Romania, and Sweden.
Excellence of clinical evidence is the heart of every well-informed decision on the development, authorization, reimbursement,...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.